{"id":7600,"date":"2025-06-24T08:00:00","date_gmt":"2025-06-24T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/"},"modified":"2025-06-24T08:00:00","modified_gmt":"2025-06-24T06:00:00","slug":"presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/","title":{"rendered":"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago"},"content":{"rendered":"
\n

Nanexa meddelar att postern med titeln "A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes" presenterades av den inom diabetesforskning v\u00e4lrenommerade Dr Hans de Vries, s\u00f6ndagen 22 juni p\u00e5 American Diabetes Association\u2019s 85:e Scientific Sessions. Postern som presenterade alla data, inklusive doscohorten med 30 mg NEX-22, mottogs mycket v\u00e4l och intresset har varit betydande f\u00f6r den f\u00f6rsta publicerade kliniska datan med en enm\u00e5nads l\u00e5ngverkande injektion av ett GLP-1 l\u00e4kemedel. En 30 mg dos av NEX-22 visar p\u00e5 en exponering upp till 36 dagar utan betydande gastrointestinala biverkningar. Detta \u00e4r inte bara mycket positivt f\u00f6r NEX-22, utan \u00e4ven f\u00f6r andra potentiella GLP-1\/GIP-formuleringar med PharmaShell.<\/strong><\/p>\n<\/div>\n

\n

ADA:s vetenskapliga sessioner \u00e4r v\u00e4rldens st\u00f6rsta diabetesm\u00f6te. De samlar \u00f6ver 11 000 deltagare fr\u00e5n hela v\u00e4rlden f\u00f6r att dela de senaste vetenskapliga uppt\u00e4ckterna och framstegen inom diabetesv\u00e5rd och innovation.<\/p>\n

\u201dVi \u00e4r mycket n\u00f6jda med den uppm\u00e4rksamhet vi har f\u00e5tt och de nya kontakter vi har knutit under detta viktiga evenemang. Vi ser att behovet \u00e4r stort av l\u00e4kemedel som f\u00f6rb\u00e4ttrar och f\u00f6renklar behandling av s\u00e5v\u00e4l typ 2-diabetes som obesitas\u201d, s\u00e4ger David Westberg, vd Nanexa. \u201dVi \u00e4r glada att vara en del i utvecklingen av viktiga l\u00e4kemedel som kan \u00f6ka m\u00e5nga m\u00e4nniskors livskvalitet\u201d.<\/p>\n

Postern \u00e4r redan digitalt tillg\u00e4nglig f\u00f6r alla ADA:s medlemmar och m\u00f6tesdeltagare och kommer fr\u00e5n augusti att finnas publikt tillg\u00e4nglig p\u00e5 ADA:s officiella portal. Postern finns \u00e4ven tillg\u00e4nglig p\u00e5 Nanexas hemsida.<\/p>\n

F\u00f6rfattare f\u00f6r postern: Dr Hans de Vries, Dr Tim Heise, Dr Grit Andersen, Kristine B\u00e4ck, Erik Westrin, Maria Nehlin, Marie G\u00e5rdmark och Dr Owe Luhr.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 vd, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r DNB Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa meddelar att postern med titeln ”A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes” presenterades av den inom diabetesforskning v\u00e4lrenommerade Dr Hans de Vries, s\u00f6ndagen 22 juni p\u00e5 American Diabetes Association\u2019s 85:e Scientific Sessions. Postern som presenterade alla data, inklusive doscohorten med 30 mg NEX-22, mottogs mycket v\u00e4l och intresset har varit betydande f\u00f6r den f\u00f6rsta publicerade kliniska datan med en enm\u00e5nads l\u00e5ngverkande injektion av ett GLP-1 l\u00e4kemedel. En 30 mg dos av NEX-22 visar p\u00e5 en exponering upp till 36 dagar utan betydande gastrointestinala biverkningar. Detta \u00e4r inte bara mycket positivt f\u00f6r NEX-22, utan \u00e4ven f\u00f6r andra potentiella GLP-1\/GIP-formuleringar med PharmaShell.<\/p>\n","protected":false},"template":"","class_list":["post-7600","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ext-nq_sv","mfn-news-tag-mfn-ext-nq-company-announcement_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nPresentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa meddelar att postern med titeln "A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes" presenterades av den inom diabetesforskning v\u00e4lrenommerade Dr Hans de Vries, s\u00f6ndagen 22 juni p\u00e5 American Diabetes Association\u2019s 85:e Scientific Sessions. Postern som presenterade alla data, inklusive doscohorten med 30 mg NEX-22, mottogs mycket v\u00e4l och intresset har varit betydande f\u00f6r den f\u00f6rsta publicerade kliniska datan med en enm\u00e5nads l\u00e5ngverkande injektion av ett GLP-1 l\u00e4kemedel. En 30 mg dos av NEX-22 visar p\u00e5 en exponering upp till 36 dagar utan betydande gastrointestinala biverkningar. Detta \u00e4r inte bara mycket positivt f\u00f6r NEX-22, utan \u00e4ven f\u00f6r andra potentiella GLP-1\/GIP-formuleringar med PharmaShell.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\\\/\",\"name\":\"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-06-24T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/","og_locale":"sv_SE","og_type":"article","og_title":"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago - Nanexa AB","og_description":"Nanexa meddelar att postern med titeln \"A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes\" presenterades av den inom diabetesforskning v\u00e4lrenommerade Dr Hans de Vries, s\u00f6ndagen 22 juni p\u00e5 American Diabetes Association\u2019s 85:e Scientific Sessions. Postern som presenterade alla data, inklusive doscohorten med 30 mg NEX-22, mottogs mycket v\u00e4l och intresset har varit betydande f\u00f6r den f\u00f6rsta publicerade kliniska datan med en enm\u00e5nads l\u00e5ngverkande injektion av ett GLP-1 l\u00e4kemedel. En 30 mg dos av NEX-22 visar p\u00e5 en exponering upp till 36 dagar utan betydande gastrointestinala biverkningar. Detta \u00e4r inte bara mycket positivt f\u00f6r NEX-22, utan \u00e4ven f\u00f6r andra potentiella GLP-1\/GIP-formuleringar med PharmaShell.","og_url":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/","url":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/","name":"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-06-24T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/presentation-av-nex-22-fas-i-data-en-enmanads-glp-1-injektion-vacker-positiv-respons-vid-adas-85e-vetenskapliga-mote-i-chicago\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Presentation av NEX-22 fas I data: En enm\u00e5nads GLP-1-injektion v\u00e4cker positiv respons vid ADA:s 85:e vetenskapliga m\u00f6te i Chicago"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}